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1. Introduction 
Diabetes mellitus (DM) is a major risk factor for micro and macrovascular complications 
(Kannel & McGee, 1979; King & Sheetz, 2002), and is associated with endothelial 
dysfunction, premature atherosclerosis (Johnstone et al., 1993; Nathan et al., 2003; Williams 
et al., 2005), and a reduced capability of neovascularization in ischemic conditions (Abaci et 
al., 1999). Hyperglycemia increases the production of superoxide (O2-) and reduces the 
bioavailability of nitric oxide (NO) resulting in the development of endothelial dysfunction 
in diabetic patients (Creager et al., 2003; Loomans et al., 2005). Exposure to oxidative stress 
induces a pro-inflammatory response and increases endothelial cell apoptosis, which leads 
to a disturbance in the endothelial monolayer. The denuded vessel wall is highly pro-
atherogenic, so fast regeneration of the endothelium is essential to prevent formation of 
atherosclerotic plaques (Dimmeler et al., 2002; Dimmeler & Zeiher, 2004).  
Patients with type 2 diabetes suffer disturbances in the intermediate metabolism of 
carbohydrates, proteins and lipids, caused by poor insulin secretion what leads to 
chronically sustained hyperglycemia. As a result, insulin-resistance develops in target 
organs and at peripheral sites, the main cause of the pathogenesis related to type 2 diabetes 
(Cerrato, 2004). Hyperinsulinemia promotes atherogenesis through cell proliferation at the 
vascular wall which produces endothelial damage (Mátthael & Stumvall, 2001). These 
endothelial alterations induce the early appearance of atherosclerosis, altering vascular 
homeostasis mainly due to the interaction of nitric oxide (NO) and free oxygen radicals. As a 
consequence of this interaction the endothelial anti-inflammatory and vasodilator properties 
are perturbed which leads to endothelial cell death, proliferation and inadequate 
restructuring of the vascular walls (Galle et al., 2003). While endothelial damage and the 
underlying inflammatory processes are often detected later, endothelial damage occurs 
before the atherosclerotic plate can be identified (Bots  et al., 1997). There are many 
biomarkers for inflammation and early endothelial dysfunction that can be used to identify 
endothelial damage in order to prevent cardiovascular disease (CD), including: high 
sensitivity C reactive protein (hs-CRP), homocysteine, microalbuminuria, glycosylated 
hemoglobin (A1c), Von Willebrand factor and plasminogen-activator inhibitor type 1 
(Reinhart et al., 2002). Elevated hs-CRP appears to be a strong predictor for future 
cardiovascular events (Tornel et al., 2003). On the other hand, much interest has been 
generated in determining serum homocysteine levels due to the relationship with CD (de 
Luis et al., 2004). Indeed, elevated serum homocysteine levels have been associated with a 
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greater risk of developing thrombosis, as well as an increase in the production of hydrogen 
peroxide and in the oxidation of low-density lipoprotein cholesterol (LDL-C), leading to 
endothelial damage (Retterstol et al., 2003). At the same time, while microalbuminuria is an 
important risk factor for nephropathy in type 1 diabetes patients, in type 2 diabetes patients 
it serves as a predictor of CD (Festa et al., 2000).  
Over the last two decades it has become evident that the endothelium is not an inert, single-
cell lining covering the internal surface of blood vessels, but in fact plays a crucial role in 
regulating vascular tone and structure. Importantly, a healthy endothelium inhibits platelet 
and leukocyte adhesion to the vascular surface and maintains a balance of profibrinolytic 
and prothrombotic activity (Libby, 2002). Endothelial dysfunction has received increasing 
attention as a potential contributor to the pathogenesis of vascular disease in diabetes 
mellitus. Under physiological conditions, there is a balanced release of endothelial-derived 
relaxing and contracting factors, but this delicate balance is altered in diabetes and 
atherosclerosis, thereby contributing to further progression of vascular and end-organ 
damage (Tan et al., 2002).  
Hyperglycemia is the major causal factor in the development of endothelial dysfunction in 
diabetes mellitus. Although the mechanisms underlying this phenomenon are likely to be 
multifactorial. Insulin resistance has been described in several diseases that increase 
cardiovascular risk and mortality, such as diabetes, obesity, hypertension, metabolic 
syndrome, and heart failure. Increasing evidence suggests that the progression of insulin 
resistance to type 2 diabetes parallels the progression of endothelial dysfunction to 
atherosclerosis. Insulin resistance is closely linked with visceral adiposity, and early data 
suggested that free fatty acids were responsible for this association (Boden & Shulman, 
2002). More recently, other plasma biomarkers produced by adipose tissue, including TNF 
and resistin, have been shown to have elevated levels during obesity and to mediate insulin 
resistance. Conversely, the expression and secretion of adiponectin, an adipocyte-specific 
protein that enhances insulin-mediated glucose uptake, is inversely correlated with fat mass 
(Lyon et al., 2003). Several studies have demonstrated that nitric oxide (NO)-mediated 
vasodilation is abnormal in patients with type 2 diabetes (Williams et al., 1996). Brachial 
artery responses were found to be abnormal to both endogenous and exogenous NO 
donors, suggesting that there was increased inactivation of NO, possibly caused by 
enhanced metabolism of NO or abnormal vascular smooth muscle cell (VSMC) responses to 
NO because of alterations in signal transduction in the guanylate cyclase pathway. Obese 
patients without frank type 2 diabetes have been shown also to have abnormal endothelial 
function (Perticone et al., 2001; Steinberg et al., 1996).  
Diminished capacity of NOS to generate NO has been demonstrated experimentally when 
ECs are exposed either in vitro or in vivo to a diabetic environment (Cosentino & Luscher, 
1998; Huszka et al., 1997; Huvers et al., 1999; Lambert et al., 1996). The EC is then a target of 
the diabetic milieu and endothelial dysfunction is thought to play an important role in the 
vasculopathy of this disease state. A large body of evidence in humans indicates that 
endothelial dysfunction is closely associated to microangiopathy and atherosclerosis in both 
types 1 and 2 diabetes mellitus (Cosentino & Luscher, 1998). This association is particularly 
true in those patients with type 1 diabetes who have either early (microalbuminuria) or late 
(macroalbuminuria) nephropathy. In these patients, a great variety of markers indicate 
endothelial dysfunction: poor EC-dependent vasodilation, increased blood levels of von 
Willebrand factor (vWF), thrombomodulin, selectin, PAI-1, type IV collagen, and t-PA 
(Cosentino & Luscher, 1998; Furchgott & Zawadzki, 1980; Schneider et al., 2002). Once 
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established, EC dysfunction can, in turn, induce alterations in vessels that worsen 
vasculopathy and progress disease. Hyperglycemia may lead to intracellular changes in the 
redox state resulting in depletion of the cellular NADPH pool. Overexpression of growth 
factors has also been implicated in diabetes with proliferation of both endothelial cells and 
vascular smooth muscle, possibly promoting neovascularization. The diabetic state is 
typified by an increased tendency for oxidative stress and high levels of oxidized 
lipoproteins, especially the so-called small, dense low-density lipoprotein. The high levels of 
fatty acids and hyperglycemia have also both been shown to induce an increased level of 
oxidation of phospholipids as well as proteins. In humans it is associated with a 
prothrombotic tendency as well as increased platelet aggregation, with tumor necrosis factor 
implicated as a link between insulin resistance, diabetes, and endothelial dysfunction; a 
hypothesis has been advanced that insulin and/or insulin precursors may be atherogenic. 
The general consensus is that the occurrence of endothelial cell dysfunction in type 1 
diabetes signifies a very high risk of micro- and macroangiopathy, and although the diabetic 
state predisposes to endothelial cell dysfunction in this disease, it is not sufficient to cause it. 
It is more likely that other agents (genes, environment) have a role in determining which 
patients will develop aggressive angiopathy and hence endothelial cell dysfunction. 
Irrespective of whether endothelial cell dysfunction is a cause or a consequence of vascular 
injury in type 1 diabetes, it is hoped that therapeutic efforts aimed at restoring endothelial 
cell function to normal will affect the natural history of vasculopathy in type 1 diabetes 
(Cosentino & Luscher, 1998). Impaired endothelium-dependent vasodilatation has been 
demonstrated in various vascular beds of different animal models of diabetes and in 
humans with type 1 and 2 diabetes. Several mechanisms of endothelial dysfunction have 
been reported, including impaired signal transduction or substrate availibility, impaired 
release of endothelium-derived relaxing factors (EDRF), increased destruction of EDRF, 
enhanced release of endothelium-derived constricting factors and decreased sensitivity of 
the vascular smooth muscle to EDRF. The principal mediators of hyperglycemia-induced 
endothelial dysfunction may be activation of protein kinase C, increased activity of the 
polyol pathway, nonenzymatic glycation and oxidative stress. Both insulin and glucose play 
a role in ET-1 release. Insulin activates ET-1 production by endothelial cells, and 
hyperglycemia leads to the formation of advanced glycation end products (AGEs) that 
promote ET-1 production by endothelial cells through the activation of transcription factor 
NF-kB. Diabetic patients, both those with type I diabetes and those with insulin resistance, 
present increased ET-1 plasma concentrations. AGEs are known to trigger vascular 
inflammation and endothelial dysfunction. The hyperglycemia associated with diabetes can 
lead to modification of macromolecules, for example, by forming AGEs. By binding surface 
receptors such as RAGE (receptor for AGE), these AGE-modified proteins can augment the 
production of proinflammatory cytokines and other inflammatory pathways in vascular 
endothelial cells. Beyond the hyperglycemia, the diabetic state promotes oxidative stress 
mediated by reactive oxygen species and carbonyl groups (Cosentino & Luscher, 1998; 
Huszka et al., 1997; Huvers et al., 1999; Lambert et al., 1996 Furchgott & Zawadzki, 1980; 
Schneider et al., 2002; Quehenberger et al., 2000; O’Brien et al., 1997).  
In patients with a high risk of developing CD, such as diabetic patients, it is important to 
improve endothelial function since vascular damage may continue even when good 
glycemic control has been achieved (Volpe et al., 2007). Accordingly, some therapeutic 
strategies have been directed towards the stimulation of distinct processes that may 
reestablish the function of the endothelium, including the use of 3-hydroxy-3-methylglutaryl 
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coenzyme A reductase inhibitors (Endemann & Schiffrin, 2004), the angiotensin converting 
enzyme (ACE) inhibitors (Schachinger et al., 2000), selective blockade of the AT1 receptor of 
angiotensin-II (ARBs) (Behrendt & Ganz, 2002) and folic acid supplementation (Libby et al., 
2002), antioxidants (Beckman et al., 2003), antidiabetics (Lund et al., 2008), insulin 
(Vehkavaara et al., 2000) and others (Grover-Páez et al., 2007). All these strategies are aimed 
at decreasing the progress of atherosclerotic disease 
Herein, we review the literature about endothelial dysfunction in diabetes mellitus with 
regards to its pathogenesis at molecular and clinical level, and possible available mode of 
therapy. 
2. Normal endothelial cell (EC) function 
The EC is no longer considered a simple barrier. In fact it is a complex organ, with paracrin 
and autocrin function, which provides a “first line” physiological defense against 
atherosclerosis. The EC lines the internal lumen of all the vasculature and serves as an 
interface between circulating blood and vascular smooth muscle cells (VSMC). In addition 
to serving as a physical barrier between the blood and tissues, the EC facilitates a complex 
array of functions in intimate interaction with the VSMC, as well as cells within the blood 
compartment (De Meyer & Herman, 1997). 
The last two decades of research have established unambiguously that the EC has a critical 
role in overall homeostasis whose functions are integrated by a complicated system of 
chemical mediators. This system exerts effects on both the surrounding VSMC and the cells 
in the blood that lead to one or more of the following alterations: (1) vasodilatation or 
vasoconstriction to regulate organ blood, (2) maintenance of fluidity of blood and avoidance 
of bleeding, (3) proinflammatory or anti-inflammatory changes, and (4) growth and/or 
changes in the phenotypic characteristics of VSMC (Wautier et al., 1996). During the last 
decade, a multitude of experimental arguments have led to the concept that NO is not only 
involved in the control of vasomotor tone but also in vascular homeostasis and neuronal 
and immunological functions. Endogenous NO is produced through the conversion of the 
amino acid, l-arginine to l-citrulline by the enzyme, NO-synthase (NOS) from which several 
isoforms have recently been isolated, purified, and cloned. NOS-type I (isolated from brain) 
and type III (isolated from ECs) are termed “constitutive-NOS” and produce picomolar 
levels of NO from which only a small fraction elicits physiological responses. NO produced 
by NOS type III in the endothelium diffuses to the vascular smooth muscle (VSM) where it 
activates the enzyme guanylate cyclase. The concomitant increase in cyclic GMP then 
induces relaxation of the VSM. The EC produces mediators that induce vasoconstriction, 
including endothelin (Haefliger, 1992) [46], prostaglandins (Viberti, 1989) and angiotensin II 
(ANG-II) (Studdy, 1983) and regulates vascular tone by maintaining a balance between 
vasodilation (NO production) and vasoconstriction (eg, A-II generation). ANG-II is 
produced in local tissues by the EC (Mombouli, 1997) [49] and exerts regulatory effects upon 
several VSMC functional activities including contraction (ie, vasoconstriction), growth, 
proliferation, and differentiation. NOS also are regulated by local concentrations of 
bradykinin (Busse et al.,1993). This peptide acts with b2 receptors on the EC cell surface 
membrane, increasing the generation of NO via NOS activation. Interestingly, the local 
concentrations of bradykinin are regulated by the activity of angiotensin converting enzyme 
(ACE). ACE breaks down bradykinin into inactive peptides (Luscher et al., 1993). 
Furthermore the EC has a prominent role in maintaining blood fluidity and restoration of 
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vessel wall integrity to avoid bleeding and plays a key role in the balance between the 
coagulation and fibrinolytic systems. In addition to its key role in growth and differentiation 
of the VSMC through the release of either promoters of growth and/or inhibitors of growth 
and differentiation and, as such, has an impact on vascular remodeling (Cowan & Langille, 
1996). However, strong evidence suggests that promotion of VSM growth is mediated by 
local production of platelet growth factor (PGF) and ANG-II (Williams, 1998). The EC is also 
involved in the production of specific molecules that have a regulatory role in inflammation 
such as leukocyte adhesion molecule (LAM), intracellular adhesion molecule (ICAM) and 
vascular cell adhesion molecule (VCAM). These molecules are denominated “adhesion 
molecules” and function to attract and “anchor” those cells involved in the inflammatory 
reaction. Very recently it has been demonstrated that the atherosclerotic process is 
associated with an increased blood level of inflammation (acute phase proteins) markers 
(Biegelsen & Loscalzo, 1999).  
2.1 Endothelial dysfunction 
Since the actions of the EC are multiple and involve several systems, alterations in EC 
function may affect one or more of these systems, either simultaneously or at distinct time 
periods. Thus, no single definition of EC dysfunction covers the whole array of possible 
disruption in normal function. In consequence, endothelial dysfunction has been defined 
pragmatically. It basically involves either an increase (or a decrease) in any of the EC-related 
chemical messenger and/or by alteration in any of the functional changes. Some examples 
of EC dysfunction include an increased permeation of macromolecules (Aird, 2005; 
Forstermann & Munzel, 2006; Ross, 1993; Vita & Keaney, 2002), increased or decreased 
production of vasoactive factors producing abnormal vasoconstriction/vasodilation, and 
increased prothrombotic and/or procoagulant activity. However, the most commonly 
accepted EC dysfunction alteration pertains to abnormalities in the regulation of the lumen 
of vessels. In this context, EC dysfunction has been defined by blunting of the vasodilatory 
response to acetylcholine or hyperemia, both of which are known to produce NO-dependent 
vasodilation. In some specific circumstances, endothelial dysfunction has been defined by a 
paradoxical vasoconstrictive response to acetylcholine or similar pharmacological agents 
(i.e., metacholine). At the heart of the definition of EC dysfunction is the measurement of EC 
function. 
Endothelial dysfunction is defined by an impaired vascular reactivity, but it also refers to a 
proinflammatory and prothrombotic state. A critical balance between endothelium-derived 
relaxing and contracting factors maintains vascular homeostasis. When this balance is 
disrupted, it predisposes the vasculature to vasoconstriction, leukocyte adherence, platelet 
activation, mitogenesis, pro-oxidation, thrombosis, impaired coagulation, vascular 
inflammation, and atherosclerosis. Endothelial dysfunction has been described in many 
cardiovascular and metabolic disorders such as hypertension, coronary heart disease, 
dyslipidemia, and type I and II diabetes. Endothelial dysfunction appears to precede the 
clinical manifestations of many of these cardiovascular disorders, hypertension for example, 
and also atherosclerosis, where abnormal vasoconstriction can be observed at the future site 
of plaque development (Aird, 2005; Endemann & Schiffrin, 2004;  Forstermann & Munzel, 
2006; Schachinger et al., 2000; Volpe et al., 2007). Thus, endothelial dysfunction is one of the 
earliest hallmarks of vascular abnormality. 
Endothelial dysfunction is thought to precede the development of atherosclerosis. Indeed, in 
the presence of cardiovascular risk factors endothelial dysfunction can be detected before 
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there is any angiographic evidence of disease or increased intima-media ratio on ultrasound 
examination. Many of the cardiovascular risk factors, including hyperlipidemia, 
hypertension, diabetes and smoking, are associated with overproduction of reactive oxygen 
species or increased oxidative stress, both of which reduce vascular nitric oxide 
bioavailability and promote cellular damage (Volpe et al., 2007). Hence, increased oxidative 
stress is considered to be a major mechanism involved in the pathogenesis of endothelial cell 
dysfunction and may serve as a common pathogenic mechanism of the effect of risk factors 
on the endothelium (Aird, 2005; Schachinger et al., 2000).  
2.2 Endothelial dysfunction and atherosclerosis 
Atherosclerosis is regarded as a dynamic and progressive disease arising from the 
combination of endothelial dysfunction and inflammation. Physiological laminar shear 
stress is of particular importance in protecting EC against abnormal activation. Endothelial 
activation can be observed under specific hemodynamic conditions such as prolonged low 
or oscillatory shear stress. These conditions are responsible for plaque formation and plaque 
vulnerability in mouse carotid artery. Both low and oscillatory shear stress increase ET-1 
expression while decreasing endothelial NO synthase (eNOS) expression. The increase in 
ET-1 expression may lead to vascular inflammation, which is central to all stages of 
atherosclerosis. ET-1 induces expression of adhesion molecules on isolated endothelial cells, 
promotes vascular inflammation and excessive oxidative stress, and mediated nuclear 
factor-kB (NFkB) activation in monocytes. In a variety of animal models of atherosclerosis, 
signs of inflammation occur hand-in-hand with incipient lipid accumulation in the artery 
wall. For example, blood leukocytes, mediators of host defenses and inflammation, localize 
in the earliest lesions of atherosclerosis, not only in experimental animals but in humans as 
well. The basic science of inflammation biology applied to atherosclerosis has afforded 
considerable new insight into the mechanisms underlying this recruitment of leukocytes. 
The normal endothelium does not in general support binding of white blood cells. However, 
early after initiation of an atherogenic diet, patches of arterial endothelial cells begin to 
express on their surface selective adhesion molecules that bind to various classes of 
leukocytes. In particular, vascular cell adhesion molecule-1 (VCAM-1) binds precisely the 
types of leukocytes found in early human and experimental atheroma, the monocyte and T 
lymphocyte. Not only does VCAM-1 expression increase on endothelial cells overlying 
nascent atheroma, but mice genetically engineered to express defective VCAM-1 show 
interrupted lesion development (Aird, 2005; Behrendt & Ganz, 2002; Forstermann & 
Munzel, 2006; Ishizuka et al., 1999; Li et al., 1993). Interestingly, the foci of increased 
adhesion molecule expression overlap with sites in the arterial tree particularly prone to 
develop atheroma. Considerable evidence suggests that impaired endogenous 
atheroprotective mechanisms occur at branch points in arteries, where the endothelial cells 
experience disturbed flow. For example, absence of normal laminar shear stress may reduce 
local production of endothelium-derived NO. This endogenous vasodilator molecule also 
has anti-inflammatory properties and can limit expression of VCAM-1. In addition to 
inhibiting natural protective mechanisms, disturbed flow can augment the production of 
certain leukocyte adhesion molecules (eg, intercellular adhesion molecule-1 [ICAM-1]). 
Augmented wall stresses may also promote the production by arterial smooth muscle cells 
(SMCs) of proteoglycans that can bind and retain lipoprotein particles, facilitating their 
oxidative modification and thus promoting an inflammatory response at sites of lesion 
formation. Once adherent to the endothelium, the leukocytes penetrate into the intima. 
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Recent research has identified candidate chemoattractant molecules responsible for this 
transmigration. For example, monocyte chemoattractant protein-1 (MCP-1) appears 
responsible for the direct migration of monocytes into the intima at sites of lesion formation. 
A family of T-cell chemoattractants may likewise call lymphocytes into the intima. Once 
resident in the arterial wall, the blood-derived inflammatory cells participate in and 
perpetuate a local inflammatory response. The macrophages express scavenger receptors for 
modified lipoproteins, permitting them to ingest lipid and become foam cells. In addition to 
MCP-1, macrophage colony-stimulating factor (M-CSF) contributes to the differentiation of 
the blood monocyte into the macrophage foam cell. T cells likewise encounter signals that 
cause them to elaborate inflammatory cytokines such as Ǆ-interferon and lymphotoxin 
(tumor necrosis factor [TNF]-ǃ) that in turn can stimulate macrophages as well as vascular 
endothelial cells and SMCs. As this inflammatory process continues, the activated 
leukocytes and intrinsic arterial cells can release fibrogenic mediators, including a variety of 
peptide growth factors that can promote replication of SMCs and contribute to elaboration 
by these cells of a dense extracellular matrix characteristic of the more advanced 
atherosclerosis lesion. Inflammatory processes not only promote initiation and evolution of 
atheroma, but also contribute decisively to precipitating acute thrombotic complications of 
atheroma. Most coronary arterial thrombi that cause fatal acute myocardial infarction arise 
because of a physical disruption of the atherosclerotic plaque (Cybulsky et al., 2001; 
Forstermann & Munzel, 2006; Ishizuka et al., 1999; Lee et al., 2001; Libby et al., 2002; 
Quehenberger et al., 2000; Schneider et al., 2002).  
3. Endothelial dysfunction and diabetes 
The role of endothelial dysfunction in type 2 diabetes is more complicated than that for type 
1. The effects of ageing, hyperlipidemia, hypertension and other factors add to the 
complexity of the problem. In contrast to patients with type 1 diabetes, endothelial 
dysfunction can also occur in patients with type 2 diabetes even when the patients have 
normal urinary albumin excretion. In fact, markers of endothelial dysfunction are often 
elevated years before any evidence of microangiopathy becomes evident (Gazis et al., 1999).  
The insulin resistance syndrome encompasses a subnormal response to insulin-mediated 
glucose disposal and frequently elevated blood pressure, hyperlipidemia and dysfi 
binolysis, even without any clinically demonstrable alteration in plasma glucose 
concentrations (Steinberg et al., 1994). There is a growing body of evidence to suggest the 
coexistence of insulin resistance and endothelial dysfunction. Insulin-induced vasodilation, 
which is partially mediated by NO release, is impaired in obese individuals who do not 
have type 2 diabetes but whom display insulin resistance (Cleland et al., 2000). 
Moreover, the obese state, a model of human insulin resistance, is associated with high 
levels of endothelin in plasma. Also blood concentrations of PAI-1 are high in patients with 
otherwise uncomplicated obesity (Calles-Escandón et al., 1996). Endothelial activation and 
acute-phase reaction correlate with insulin resistance and obesity in type 2 diabetic patients 
(Leinonen et al., 2003). 
Abnormalities in vascular reactivity and biochemical markers of endothelial cell activation 
are present early in individuals at risk of developing type 2 diabetes. The vasodilatory 
responses to acetylcholine were reduced in healthy normoglycemic subjects who have first 
degree diabetic relatives. The plasma levels of endothelin-1 were significantly higher in 
subjects with impaired glucose tolerance and patients with type 2 diabetes without vascular 
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complications compared with healthy normoglycemic subjects with no history of type 2 
diabetes in a first-degree relative (Caballero ET AL., 1999). In addition there is a significant 
association between endothelial dysfunction and insulin resistance in young first degree 
relatives of DM subjects independent of the classic cardiovascular risk factors (Balletshofer 
ET AL., 2000).  
In a case-cohort study, using the Monitoring of Trends and Determinants in Cardiovascular 
Disease (MONICA)/ Cooperative Research, men and women with elevated levels of sE-
selectin had a significantly increased risk of type 2 diabetes after multivariable adjustment. 
Hazard ratios (95% CIs) comparing tertile extremes of sE-selectin were 2.63 (1.79–3.88) and 
1.71 (1.07–2.75) for men and women, respectively. Elevated levels of sICAM-1 were also 
associated with an increased risk of type 2 diabetes; however, the association was not 
independent of other diabetes risk factors including E-selectin, while vWF was not 
associated with risk of type 2 diabetes (Thorand et al., 2006). A prospective, nested case-
control study within the Nurses’ Health Study, has found elevated E-selectin and ICAM-1 
levels can predict incident diabetes in logistic regression models conditioned on matching 
criteria and adjusted for body mass index (BMI), family history of diabetes, smoking, diet 
score, alcohol intake, activity index and postmenopausal hormone use. Adjustment for waist 
circumference instead of BMI or further adjustment for baseline levels of C-reactive protein, 
fasting insulin, and HbA1c or exclusion of cases diagnosed during the first 4 years of follow-
up did not alter these associations (Meigs et al., 2004). 
In the other hand, in diabetes, glycation, tissue oxidation and endothelial function are all 
abnormal and predisposing to microvascular complications but interrelationships are 
complex with glycation appearing most direct (Wen et al., 2002). The patients with 
microalbuminuria, unlike those without it, are characterized by longer course of diabetes, 
more pronounced lipid exchange disorder, more variable arterial pressure, higher pressure 
load index, elevated activity of lipid peroxidation (LP) processes and prominent disorder of 
NO-producing endothelial function. All improve with treatment (Ametov et al., 2005). The 
Endothelium-dependent vasodilation was impaired in the microalbuminuric patients 
compared with the normoalbuminuria patients and the healthy controls. Plasma PAI-1 and 
vWF levels increased in the microalbuminuric patients compared with the levels in the 
normoalbuminuric patients and in the healthy controls (Yu et al., 2005). 
In addition, in type 2 diabetes mellitus as in type 1, increased calpain (calcium-dependent 
protease) activity in response to hyperglycemia may play a role in diabetic cardiovascular 
disease. Immunoprecipitation studies revealed that glucose induces loss of NO via a 
calpain-dependent decrease in the association of hsp90 with endothelial NOS. In addition, 
inhibition of calpain activity decreased endothelial cell surface expression of the pro-
inflammatory adhesion molecules ICAM-1 and VCAM-1 during hyperglycemia (Stalker et 
al., 2003). Furthermore inhibition of PKC activity reduces leukocyte-endothelium 
interactions by suppressing surface expression of endothelial cell adhesion molecules in 
response to increased oxidative stress (Booth et al., 2002).  
In diabetes associated with diabetic microangiopathy, compared with non diabetics, 
asymmetric dimethylarginine [ADMA]; an endogenous inhibitor of NOS, serum TNF-alpha 
and soluble TNF receptor I (sTNFR-I) has been assessed in a study which concludes that the 
serum sTNFR-I and VEGF levels were signifi cantly increased, but no difference in the 
serum TNF-alpha, sTNFR-II, and ADMA levels between uncomplicated diabetic patients 
and in non diabetics (Makino et al., 2005). Increased levels of vWF antigen, t-PA antigen and 
PAI-1 activity were seen in impaired glucose tolerance (IGT) and diabetics compared with 
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the normal glucose tolerance (NGT). Tissue factor pathway inhibitor TFPI activity and 
thrombomodulin levels were increased in all elderly subjects, with positive association 
between HbA (1c), TFPI activity and vWF antigen. Fasting blood glucose levels correlated 
with vWF antigen, t-PA antigen and PAI-1 activity, whereas urine albumin excretion 
correlated with TFPI activity, vWF antigen and PAI-1 activity. Serum insulin levels 
correlated strongly not only with vWF antigen and t-PA antigen but also with PAI-1 
activity. This correlation did not change after further adjustment for serum glucose and 
HbA(1c), which may suggest that in the elderly subjects, impaired fibrinolysis is probably 
associated with insulin resistance (Leurs et al., 2002). The above reflect a prothrombotic state 
associated with an insulin resistance state, an increased vWF release, raised sP-Sel and 
TNFalpha levels and, may be, low NO bioavailability, which could lead to a higher risk of 
development of thrombotic events in hypertensive diabetic patients (Ouvina et al., 2001).  
Besides this, NADPH oxidase gene expression is increased in circulating lymphomonocytes 
from patients with DM, and this increased gene expression is dependent upon metabolic 
control. Hyperglycemia can mediate its adverse effects through the activation of protein 
kinase C. Recent study has shown an increase in membrane-associated PKC beta 2 activity 
in monocytes from patients with DM. This activity was reduced by 40% in the euglycemic 
condition (Avogaro et al., 2001). Further more patients with Type 2 diabetes with good 
residual C-peptide secretion are better protected from endothelial dysfunction that those 
with poor C-peptide secretion (Manzella et al., 2003).  
3.1 Hyperglycemia as the major causal factor in the development of endothelial 
dysfunction  
Clinical trials have identified hyperglycemia as the key determinant in the development 
of chronic diabetic complications. The formation of advanced glycation end products 
(AGEs) is an important biochemical abnormality accompanying diabetes mellitus and, 
likely inflammation in general. Although the mechanisms underlying this phenomenon 
are likely to be multi-factorial, recent in-vivo and in- vitro studies have indicated a crucial 
role of the diacylglycerol (DAG)-protein kinase C (PKC) pathway in mediating this 
phenomenon. PKC may have multiple adverse effects on vascular function, including the 
activation of superoxide-producing enzymes such as the nicotinamide adenine 
dinicleotide phosphate (NADPH) oxidase as well as increased expression of a 
dysfunctional, superoxide-producing, uncoupled endothelial nitric oxide synthase (NOS 
III). PKC-mediated superoxide production may inactivate NO derived from endothelial 
NOS III, and may inhibit the activity and/or expression of the NO downstream target, the 
soluble guanylyl cyclase. The effects of AGEs on vessel wall homeostasis may account for 
the rapidly progressive atherosclerosis associated with diabetes. Driven by hyperglycemia 
and oxidant stress, AGEs form to a greatly accelerated degree in diabetes. Within the 
vessel wall, collagen-linked AGEs may “trap” plasma proteins, quench NO activity and 
interact with specific receptors to modulate a large number of cellular properties. On 
plasma low density lipoproteins (LDL), AGEs initiate oxidative reactions that promote the 
formation of oxidized LDL. The interaction of AGEs with endothelial, as well as with 
other cells accumulating within the atherosclerotic plaque, such as mononuclear 
phagocytes and smooth muscle cells, provides a mechanism to augment vascular 
dysfunction. Specifically, the interaction of AGEs with vessel wall component increases 
vascular permeability, the expression of procoagulant activity and the generation of 
reactive oxygen species, resulting in increased endothelial expression of endothelial 
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leukocyte adhesion molecules (Farhangkhoee et al., 2006), while acute hyperglycemia and 
hyperinsulinemia induced vasodilatation is not accompanied by changes in microvascular 
permeability or endothelial markers. The effects of acute glycemia on plasma nitric oxide 
(NO; nitrite plus nitrate) levels, Cu-Zn Superoxide dismutase (Cu-Zn SOD) activity and 
thiobarbituric acid-reactive substances (TBARS) levels were studied in age-matched 
female subjects before and two hours after glucose loading. Plasma NO levels were 
significantly higher in subjects with diabetic glucose tolerance (DGT) than in subjects with 
normal glucose tolerance (p < 0.001) and impaired glucose tolerance (IGT) (p < 0.05) at 
baseline. TBARS levels were significantly elevated in subjects with DGT and IGT (p < 
0.001 and p < 0.001). Cu-Zn SOD activities were significantly increased in subjects with 
NGT, and were significantly decreased in subjects with IGT and DGT (p < 0.001 and p < 
0.001) after glucose loading; suggest that NO availability was decreased when the blood 
glucose levels were only moderately elevated above normal levels. This might be related 
with the enhanced oxidative stress (Konukoglu et al., 2003). Other studies examined the 
effect of acute hyperglycemia on endothelium-dependent vasodilation in patients with 
DM or impaired glucose metabolism in- vivo by plethysmography. The vasodilatory 
response to acetylcholine at infusion rates of 7.5, 15, and 30 microg/min was studied in 
the fasting state and at two levels of hyperglycemia, which were achieved by the infusion 
of glucose, insulin and somatostatin. The vasodilatory response to acetylcholine was 
measured by calculating the forearm blood fl ow ratio (FBFR), defined as the measured 
forearm blood flow at a specific acetylcholine infusion rate divided by the baseline 
forearm blood flow without acetylcholine infusion. The induction of hyperglycemia 
resulted in a significant reduction in FBFR for all rates of acetylcholine infusion and 
suggests the importance of hyperglycemia in the development of endothelial dysfunction 
observed in patients with DM or impaired glucose metabolism (Bhargava et al., 2003).   
4. Endothelial dysfunction and therapeutic intervention  
Several pharmacological interventions have been used to improve endothelial function in 
patients with type 2 diabetes mellitus in this part of the chapter we will mention the most 
important issues. 
4.1 Antidiabetics 
4.1.1 Metformin 
Metformin is an oral anti-hyperglycaemic agent which enhances insulin sensitivity and 
lowers hepatic glucose output (Hundal & Inzucchi, 2003). In obese patients with T2DM, 
metformin is currently the drug of first choice due to its bilateral effect on glycaemic 
regulation and cardiovascular protection (Inzucchi 2002; (Union Kingdom Prospective 
Diabetes Study, [UKPDS], 1998 (UKPDS,1998). However, obese and non-obese patients with 
T2DM experience a similar cardiovascular risk (Adlerberth et al., 1998; Manson et al., 1991) 
and the use of metformin even in the non-obese patients with T2DM might be beneficial as 
well.  
In predominantly obese patients with T2DM, metformin has previously been shown to 
decrease levels of vWf, sVCAM-1, ADMA, methylglyoxal (i.e. a major precursor in the 
formation of AGE) and albuminuria (Abbasi et al., 2004; Asagami et al., 2002; Amador-
Licona et al., 2000; Beisswenger et al.,1999; De Jager et al., 2005; Nagi & Yudkin., 1993) and 
either decrease or having no significant effect (Abbasi et al., 2004; Asagami et al., 2002; Chu 
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et al., 2002; De Jager et al., 2005; Natali et al., 2004; Testa et al., 1996) on circulating levels of 
CRP, TNF-a, PAI-1-ag, t-PA-ag, sICAM-1 and sE-selectin.  
Recent in vitro studies have suggested that metformin activates the intracellular ‘fuel-
sensor’, i.e. the AMP activated kinase (AMPK). The activated AMPK, in turn, inhibits the 
TNF-a-induced activation of the nuclear transcription factor, NF-kB, and hereby the NF-
kBinduced gene expression of sICAM-1, sVCAM and sE-selectin (Hattori et al., 2006; Isoda 
et al., 2006). In the other hand, in a recent study comparing metformin versus repaglinide, a 
decrease was observed in several CVD biomarkers, may be explained by actions of 
metformin via the pathway of AMPK, TNF-a and NF-kB. The changes from first-period 
baseline in the levels of TNF-ǂ were not significantly different from zero during either of the 
two treatments. 
Therefore, besides AMPK other, yet unknown, mechanisms (promoting, inhibitory and/or 
feedback) might contribute to the effect of metformin as well as repaglinide on CVD 
biomarkers. This is also underscored by the attenuating effect of metabolic variables on the 
treatment effects on several CVD biomarkers in that study  
4.1.2 Thiazolidinediones  
Thiazolidinediones enhances insulin-mediated glucose uptake into insulin target tissues, 
through activation of peroxisome proliferator-activated receptor (PPAR) (Mudaliar & 
Henry, 2001). They have direct effects on adipose tissue by suppression TNF and, possibly, 
leptin expression; suppress lipolysis and thus decrease plasma free fatty acid concentrations 
and increase plasma adiponectin levels (Hauner, 2002) and exert direct effects on insulin-
mediated glucose transport in skeletal muscle and the heart (Bishop-Bailey, 2000). 
Thiazolidinedione administration reverses insulin resistance and many components of the 
metabolic syndrome. Treatment is generally associated with increased HDL cholesterol 
levels; decreased blood pressure, plasma triglyceride levels, small dense LDL cholesterol 
particles, PAI-1 levels and albumin excretion rates; in addition to decreased glucose levels 
and reduced hemoglobin A1C levels (Freed et al., 2002). PPAR ligands also improve 
endothelial function (Dandona & Aljada, 2004). Several studies have demonstrated 
improvements in brachial artery reactivity in patients with diabetes. (Caballero et al., 2003).  
Rosiglitazone, improves coronary artery endothelial function in patients with insulin 
resistances who have no traditional risk factors for atherosclerosis as well as no impaired 
glucose tolerance or diabetes (Quiñones et al., 2002). With an increase in insulin sensitivity 
and a drop in fasting insulin and free fatty acid levels, thiazolidinediones in combination 
with hormone therapy (HT) in postmenopausal women is, however, have shown in study to 
attenuates endothelial function (Honisett et al., 2004). 
The mechanisms by which thiazolidinediones improve endothelial-dependent blood fl ow 
are unknown, but likely involve several effects. First, as described above; it has an important 
anti-inflammatory effects that involve decreasing circulating adipokines levels (eg, TNF, 
PAI-1, leptin), which are reflected by reduced high-sensitivity C-reactive protein levels; 
increasing adiponectin levels; decreasing vascular expression of adhesion molecules 
(Wakino et al., 2002). Second, insulin is a vasodilator stimulating expression of eNOS 
through the phosphatidylinositol 3-kinase (PI3K) pathway (Zeng et al., 2000). This effect of 
insulin is blunted in patients with insulin resistance (Kuboki et al., 2000). PPAR- is 
expressed in endothelial cells, and its ligands have been reported to enhance NO 
production, possibly by stimulating the PI3K pathway and hence expression of eNOS (Kim 
et al., 2002). Third, PPAR- ligands improve several components of the metabolic syndrome 
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that could adversely affect endothelial function, including low HDL cholesterol levels, high 
triglyceride and free fatty acid levels, hypertension and carbohydrate intolerance. PPAR-
ligands also decrease oxidative stress and thus are able to improve the vascular balance 
between NO and vasoconstrictors (Bagi et al., 2004). 
Rosiglitazone administration for 12 weeks was shown to improve insulin sensitivity and 
decrease asymmetric dimethylarginine levels. An endogenous inhibitor of NOS, is 
associated with reduced NO–mediated vasodilation and enhanced adherence of 
mononuclear cells to the endothelium (Stuhlinger et al., 2002). In recently performed a 
double-blind crossover trial of 12 patients with recently diagnosed type 2 diabetes concludes 
that insulin resistance is a major contributor toward endothelial dysfunction in type 2 
diabetes; both endothelial dysfunction and insulin resistance are amenable to treatment by 
rosiglitazone (Pistrosch et al., 2005).  
Recently studies have shown that Rosiglitazone ameliorated glomerular hyperfiltration in 
early type 2 diabetes, improved NO bioavailability and lessened renal end-organ damage in 
type 2 diabetes with microalbuminuria (Pistrosch et al., 2004) and Pioglitazone improves 
endothelial dysfunction independently from the observed benefits on insulin sensitivity and 
beta-cell function in patients with newly diagnosed type 2 diabetes and CAD and may 
exerts additional effects on endothelial function beyond metabolic control (Forst et al., 2005). 
Furthermore the GATE study may provide the rationale and impetus for the aggressive 
treatment of insulin-resistant patients with glitazone therapy (Hubacek et al., 2004).  
Recently a study was published that used the addition of pioglitazone and ramipril to 
intensive insulin therapy in Type 2 diabetic patients that which showed that pioglitazone 
improves vascular dysfunction by different mechanisms. 
In this study, they demonstrated that the addition of either the insulin sensitizer 
pioglitazone or the ACE-blocking agent ramipril further improves vascular dysfunction and 
markers of inflammation independent of glycemic control. their data indicate that 
pioglitazone primarily enhances endothelial-mediated, whereas ramipril augments 
endothelial-independent, vasodilation. These different vascular effects, combined with the 
observation that pioglitazone increases the vasodilator adiponectin concentration, while 
ramipril reduces the vasoconstrictor endothelin-1 levels, suggest that different and 
complementary mechanisms underlie the observed improvements in vascular reactivity. In 
agreement with previous studies, pioglitazone therapy also was accompanied by a 
reduction in plasma fatty acids and triglyceride concentrations, both of which may play a 
role in the correction of vascular dysfunction (Natali et al., 2004; Pfutzner et al., 2005; 
Wajcberg et al., 2007) [120-122]. Previous studies (Natali et al., 2004; Pfutzner et al., 2005) 
also have shown that pioglitazone can improve endothelial dysfunction independent of 
changes in blood glucose levels. Thus, it is likely that the beneficial effects of TZDs on 
vascular function are mediated by 1) direct effects on the vascular endothelium, 2) improved 
glycemic control, and 3) enhanced insulin-mediated glucose metabolism. Pioglitazone did 
not improve endothelial- independent vasodilation beyond that observed with intensive 
insulin therapy alone.  
4.1.3 Meglitinides 
Recently the repaglinide administration, showed that it improves brachial reactivity and 
declines oxidative stress indexes. in vitro through good control of postprandial glucose 
levels, in agreement with previous data (Ceriello, 2004; Gomes et al., 2004; Gross et al., 2003). 
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In addition, the relationship between changes in 2-h plasmaglucose levels and brachial 
reactivity is independent of the main metabolic parameters but is dependent on the TBARS 
and TEAC levels. The latter data, according to a previous study showing that endothelial 
dysfunction is present in the postprandial state in type 2 diabetic patients (Ceriello et al., 
2004), they support the hypothesis that 2-h plasma glucose levels are the main factor 
determining oxidative stress and endothelial dysfunction and that a tight control of 
postprandial glucose excursion—as those found after repaglinide—is a key point for 
preventing endothelial dysfunction and macroangiopathy (Manzella et al., 2005). 
Furthermore, because the modulation of vascular tone is mediated by NO and endothelium-
derived hyperpolarizing factor (EDHF), and because the role of EDHF in modulating 
vascular smooth muscle contraction is mediated by KCa channels on vascular smooth 
muscle (Georgescu et al., 2001; Inokuchi et al., 2003), While Nateglinide an oral antidiabetic 
insulinotropic agent neither improved nor impaired myocardial blood flow in Type 2 
diabetic patients (Bengel et al., 2005).  
4.1.4 -glucosidase inhibitors 
4.1.4.1 Acarbose 
Acarbose inhibits enzymes (glycoside hydrolases) needed to digest carbohydrates, to be 
specific, alpha-glucosidase enzymes in the brush border of the small intestines and 
pancreatic alpha-amylase. Pancreatic alpha-amylase hydrolyzes complex starches to 
oligosaccharides in the lumen of the small intestine, whereas the membrane-bound 
intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides 
to glucose and other monosaccharides in the small intestine. Inhibition of these enzyme 
systems reduces the rate of digestion of complex carbohydrates. 
There is a randomized Crossover Study with Acarbose, that shows the effects of a single 
administration of acarbose on postprandial glucose excursion and endothelial dysfunction 
in type 2 diabetic patients. In this study the authors hypothesize that acarbose might reduce 
macrovascular complication by avoiding endothelial injury in postprandial hyperglycemic 
status (Shimabukuro et al., 2006)].  
A potential mechanism by which postprandial hyperglycemia impairs endothelial function is 
the generation of reactive oxygen species (ROS) (Sheetz & King, 2002). (Yano et al., 2004) 
reported that a short-time exposure (3 h) to 25 mmol/liter glucose increased intracellular ROS 
generation in cultured bovine aortic endothelial cells. Previously has been reported that 
nateglinide, a phenylalanine-derived insulin secretagogue, could also improve postchallenge 
endothelial function in type 2 diabetic patients (Shimabukuro et al., 2004). 
Collectively, postprandial endothelial function could be improved by an intervention to 
reduce postprandial glucose peak at least in part. (Vallejo et al., 2005) reported that 
acetylcholine-induced endothelium-dependent relaxations were impaired in aortic and 
mesenteric vessels isolated from streptozotocin-induced diabetic rats, and such endothelial 
dysfunction was improved either with suppression of blood glucose levels by acarbose or with 
ROS suppression by superoxide dismutase. Taken together, it was still possible that 
suppression of postchallenge hyperglycemia by acarbose decreased generation of ROS and the 
ROS-mediated impairment of endothelial function, although we could not detect changes of 
urinary 8-epi-prostaglandin-F2, one reliable marker of whole-body oxygen stress, during the 
test meal loading. Previous studies showed that insulin can induce either vasodilation by 
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increasing NOx levels or vasoconstriction by stimulating endothelin-1 levels (Piatti et al., 2003) 
and the net balance between vasodilator and vasoconstrictor effects of insulin is altered in 
diabetic patients in favor of a relative vasoconstriction (Cardillo et al., 2002). In the study of 
(Shimabukuro et al., 2006), there were no significant differences in plasma NOx and 
endothelin-1 levels before and after meal ingestion in control and diabetic subjects. Because 
plasma levels of endothelin-1 may not truly reflect the activity of endothelin-1 and endothelin 
receptor subtype A (ETA)-dependent mechanism could be involved in vascular derangements 
of diabetic condition, additional future studies need to be done. 
4.1.4.2 Miglitol 
Miglitol has been launched as an ǂ-GI, which possesses particular pharmacokinetics. 
Miglitol is absorbed rapidly and almost completely from the small intestine after oral 
administration (Ahr et al., 1997). Thus, it can strongly suppress the elevation of blood sugar 
levels shortly after a meal while causing relatively fewer side-effects in the digestive system 
such as abdominal bloating and diarrhea. The administration of miglitol has been 
demonstrated to suppress the progression of atherosclerosis associated with controlling 
fluctuations of blood sugar in apolipoprotein E knockout mice (Mita et al., 2007). 
Recently (Makoto et al., 2010), reported the post-prandial effects of a single administration 
of miglitol and voglibose on endothelial function and changing levels of glucose, insulin, 
lipids, glucagon-like peptide (GLP)-1, and gastric inhibitory polypeptide (GIP) that were 
compared after a standard meal loading in 11 diabetic patients with CAD, using a placebo 
controlled cross-over design. They showed the changing levels of glucose, insulin and 
triglycerides at 60 min were significantly lower in the miglitol group than in the voglibose 
and placebo groups (all P<0.01). GLP-1 levels that were significantly higher at 120 min 
(P<0.05) and GIP levels were significantly lower at 30 min and 60 min (P<0.05) in the 
miglitol group compared to other treatments. The reactive hyperemia duration at 120 min 
was significantly maintained in the miglitol group compared to the other groups.  
The precise mechanisms are still unidentified, but negative correlations between endothelial 
function and the indices of changing of post-prandial glucose levels were demonstrated. A 
previous study also reported the association between post-prandial endothelial function and 
post-prandial glucose levels (Shimabukuro et al., 2006). In addition, swings in glucose levels 
affect monocyte adhesion to the endothelium in animal models (Mita et al., 2007) and 
oscillating glucose levels cause much deleterious impairment on endothelial function rather 
than constant high glucose (Ceriello et al., 2008). Therefore, post-prandial endothelial 
function could, in part, be improved by amelioration of post-prandial glucose levels by 
administration of miglitol.  
5. Insulin therapy 
The UK Prospective Diabetes Study (UKPDS) showed that intensive blood glucose control 
with insulin or sulfonylureas, both of which significantly increase circulating free insulin 
concentrations, retards the development of microvascular complications. The incidence of 
myocardial infarction decreased by 16%, which was almost statistically significant (P =.052). 
Neither insulin nor sulfonylureas had adverse effects on cardiovascular outcome (Union 
Kingdom Prospective Diabetes Study, [UKPDS], 1998 (UKPDS, 1998). 
Considering this, an “in vivo” study was reported (Vehkavaara et al., 2000),  in which the  
endothelial function was measured in 18 type 2 diabetic patients previously treated with 
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metformin (1000 mg BID, n514; 500 mg BID, n54) before and 6 months after combination 
therapy with bedtime human isophane insulin and metformin (effect of insulin therapy). A 
control group of 27 normal subjects was studied to determine whether endothelial function 
was abnormal in the type 2 diabetic patients. 
In this study a total of 75 in vivo endothelial function tests (intrabrachial artery infusions of 
endothelium-dependent [acetylcholine] and -independent [sodium nitroprusside] 
vasoactive agents) were performed in 18 type 2 diabetic patients and 27 matched normal 
subjects. These tests were performed before and 6 months after combination therapy with 
insulin and metformin and before and 6 months after metformin therapy only. Before 
insulin therapy, blood flow responses to acetylcholine were significantly blunted in type 2 
diabetic patients compared with normal subjects. During insulin therapy, the acetylcholine 
response increased by 44% (P<0.05). Insulin therapy also significantly increased the blood 
flow responses to both low and high doses of sodium nitroprusside. They conclude that 
insulin therapy improves endothelium-dependent and -independent vasodilatation. These 
data support the idea that insulin therapy has beneficial rather than harmful effects on 
vascular function. 
In the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 
study, patients with an acute myocardial infarction, who received insulin acutely and 
chronically, had a 28% reduction in mortality rate compared with those of patients who 
continued their existing therapies Coronary endothelial dysfunction, defined as impaired 
vasodilatory response to intracoronary infusion of acetylcholine (ACh), is an independent 
predictor of vascular events even after adjustment for traditional cardiovascular risk factors 
(Schachinger et al., 2000; Suwaidi et al., 2000). Recently, these findings were extended to 
measurements performed across the forearm vascular bed (Heitzer et al., 2001; Perticone et 
al., 2001).  
Regarding insulin, acute studies have shown that a physiological increase in the circulating 
insulin concentration potentiates ACh-induced but not sodium nitroprusside (SNP)-induced 
vasodilatation (Rask-Madsen et al., 2001; Taddei et al., 1995). In studies addressing effects of 
long-term insulin therapy on endothelial function, we have previously shown that 
endothelium-dependent and endothelium independent blood flow in forearm resistance 
vessels improves during 6 months of combination therapy with bedtime neutral protamine 
Hagedorn (NPH) insulin and metformin, while continuation of long-term metformin 
therapy had no effect on vascular function (Vehkavaara et al., 2000). In another study of 
patients with type 2 diabetes, 2 months of insulin therapy tended (P<0.09) to increase the 
blood flow response to ACh and restored the ability of insulin to acutely potentiate ACh-
induced vasodilatation (Rask-Madsen et al., 2001).  
Insulin glargine is a long-acting insulin analogue. Compared with regular human insulin in 
vitro, insulin glargine was, in one study, reported to have a 6.5-fold higher affinity for 
insulinlike growth factor 1 (IGF-1) receptors in transfected baby hamster kidney cells 
(Kurtzhals et al., 2000). In contrast to these results, a recent study found equivalent binding 
of insulin glargine and regular human insulin to insulin and IGF-1 receptors in skeletal 
muscle cells (Ciaraldi et al., 2001). IGF-1 is a potent stimulator of blood flow (Pendergrass et 
al., 1998). It is therefore not self-evident that effects of glargine on vascular function are 
similar to those of human insulin.  
(Vehkavaara & Yki-Järvinen, 2004), determined the effects of 3.5 years of addition of insulin 
glargine to previous metformin therapy on in vivo endothelial function in patients with type 
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2 diabetes. The data were compared with data from a group of normal subjects. A total of 49 
in vivo endothelial function tests, intrabrachial artery infusions of endothelium dependent 
(acetylcholine [ACh]) and endothelium-independent (sodium nitroprusside [SNP]) 
vasoactive agents, were performed in 11 patients with type 2 diabetes and 16 matched 
normal subjects. The tests in the type 2 diabetic patients were performed before and after 6 
months and 3.5 years of combination therapy with insulin glargine and metformin. The 
study conclude that insulin glargine therapy improves endothelium-dependent and 
endothelium-independent vasodilatation. These data support the idea that long-term insulin 
therapy has beneficial rather than harmful effects on vascular function in type 2 diabetes. 
6. Inhibition of renin angiotensin pathway  
Angiotensin II has several pro-oxidative effects on the vasculature, decreasing NO 
bioavailability and resulting in vascular injury. ACE inhibitors are known to improve 
endothelial dysfunction, but the ability of angiotensin receptor blockers to improve 
endothelial dysfunction is less clear (Mancini et al., 1996). Both drug classes consistently 
prevent coronary artery (particularly in the case of ACE inhibitors), stroke, and diabetic 
microvascular complications of nephropathy and retinopathy (McFarlane et al., 2003).  
Inhibition of the renin-angiotensin system is associated with reduced incidence of new-onset 
diabetes. In the Heart Outcomes Prevention Evaluation (HOPE) study) (Yusuf et al., 2001), 
the incidence of diabetes was 32% lower in the ramipril-treated group than in the placebo 
group. In the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study 
(Dahlof et al., 2002), losartan was associated with 25% less new-onset diabetes compared 
with atenolol. The mechanisms responsible for the reduced incidence of diabetes observed 
during these trials are unknown, although possible mechanisms include increased plasma 
bradykinin levels, which improves insulin-mediated glucose uptake (Duka et al., 2001), 
improved endothelial function, increased vascular NO activity and reduced vascular 
inflammation.  
Moreover, In view of the pathogenetic role of the imbalance between angiotensin II and NO 
in target-organ damage, it is a logical approach to target the renin-angiotensin system 
(RAS). Considering this, it has been observed that ACE inhibitors prevent the formation of 
angiotensin II from angiotensin I, whereas the angiotensin II receptor blockers (ARBs) 
specifically prevent the binding of angiotensin II to type 1 receptors (Burnier, 2001).  
ACE inhibitors lead to accumulation of bradykinin, known to improve endothelial function, 
whereas ARBs elicit stimulation of the angiotensin II AT2 receptors and modulate 
peroxisome proliferator–activated receptor-receptors. 
The clinical relevance of these additional effects of ACE inhibitors and ARBs is 
controversial. So far, the effects of ACE inhibitors and ARBs have been examined mainly in 
the peripheral circulation. Although small sample sizes have been used, significant 
improvement of endothelial function has been observed for both compounds used in the 
current trial. 
Ramipril significantly improved renal endothelial function in normotensive, 
normoalbuminuric men with type 1 diabetes (Komerset al., 2000), and telmisartan increased 
endothelial function in treatment-naive hypertensive patients (Svolis et al., 2002). Recently, 
(Schmieder, 2007), reported the results head-to head comparisons examining the effects of 
RAS blockade on renal endothelial function in patients with type 2 diabetes and 
hypertension, who are known to have a very high risk of cardiovascular and renal 
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morbidity (Delles et al., 2002; Schmieder, 2005). He studied in a multicenter, prospective, 
double-blind, forced-titration, randomized study, 96 patients with type 2 diabetes, 
hypertension, glomerular filtration rate 80 ml/min, and normo-or microalbuminuria were 
treated once daily with 40/80 mg telmisartan or 5/10 mg ramipril for 9 weeks. He 
concluded that in patients with type 2 diabetes, telmisartan and ramipril both increased NO 
activity of the renal endothelium significantly, which in turn may support the preservation 
of cardiovascular and renal function.  
7. Statin and endothelial dysfunction 
Several clinical trials have demonstrated that statin treatment not only reduces serum 
cholesterol levels in hypercholesterolemic patients, but also substantially decreases the risk 
of cardiovascular disease (Shepherd et al., 1995). In current clinical use, statins can reduce 
LDL cholesterol levels by an average of 20%–35%, with a corresponding 30%–35% reduction 
in major cardiovascular outcomes. Decreases in serum cholesterol levels could account for 
the observed risk reduction, since LDL cholesterol has a strong, well documented 
association with cardiovascular risk, and since plasma LDL apheresis has been shown to 
improve both endothelium-dependent vasodilation and cardiovascular risk in 
hypercholesterolemic patients (Tamai et al., 1997). Several studies, however, have shown 
that improvements in endothelial function can occur before reductions in serum cholesterol 
levels. These acute effects are in agreement with other studies that have reported 
improvements in endothelial function after statin administration that do not correlate with 
reductions in serum LDL cholesterol levels, and it has been observed that statins can 
decrease high-sensitivity C-reactive protein levels by 30%–40%, independent of their 
cholesterol lowering capacities (Ansell et al., 2003). 
7.1 Rosuvastatin 
In this context, the Justification for the Use of Statins in Prevention: an Intervention Trial 
Evaluating Rosuvastatin (JUPITER) Study (Ridker et al., 2008), that randomly assigned 
17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol 
levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive 
protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and 
followed them for the occurrence of the combined primary end point of myocardial 
infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death 
from cardiovascular causes. The trial was stopped after a median follow-up of 1.9 years 
(maximum, 5.0). Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity 
C-reactive protein levels by 37%.  
The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in 
the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56 95% 
confidence interval [CI], 0.46 to 0.69; P<0.00001), with corresponding rates of 0.17 and 0.37 
for myocardial infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P = 0.0002), 0.18 and 0.34 
for stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P = 0.002), 0.41 and 0.77 for 
revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 
and 0.85 for the combined end point of myocardial infarction, stroke, or death from 
cardiovascular causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 
for death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P = 0.02). The conclusion of 
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this trial is that in apparently healthy persons without hyperlipidemia but with elevated 
high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of 
major cardiovascular events.  
7.2 Atorvastatin 
Undoubtedly the most important study to demonstrate the pleiotropic effect of 
atorvastatin has been The Reversal of Atherosclerosis with Aggressive Lipid Lowering 
(REVERSAL) study (Nicholls et al., 2006), this clinical trial was carried out to determine 
the influence of increasing body mass index (BMI) on plasma lipids, C-reactive protein, 
plaque burden as determined by intravascular ultrasound, and the serial change in these 
parameters with a moderate or intensive lipid-lowering strategy. In this clinical trial 
patients were randomized to receive an intensive lipid-lowering strategy with 80 
mg/day of atorvastatin and a pravastatin placebo or a moderate lipid-lowering strategy 
with 40 mg/day of pravastatin and an atorvastatin placebo. Treatments were 
administered for an 18-month period. Patients with a higher BMI were younger, more 
likely to be women, and had a greater prevalence of hypertension, diabetes, and the 
metabolic syndrome. Although a higher BMI was associated with a lower high-density 
lipoprotein level and higher triglyceride and C-reactive protein levels, there was no 
apparent influence of BMI on plaque burden. However, with the intensive lipid-lowering 
strategy, a greater BMI was associated with a lower proportionate decrease in low-
density lipoprotein (49.1 ± 21.4% vs 43.0 ±22.4%, p < 0.008) and a greater proportionate 
decrease in C-reactive protein (39.7% vs 33.3%, p <0.04). Further, although moderate and 
intensive lipid-lowering strategies halted plaque progression in subjects with a lower 
BMI (median progression rates +1.5% and +1.2%, respectively), a significant effect on 
plaque progression rates was seen only with adoption of an intensive lipid lowering 
strategy in the most obese subjects (median progression rate -1.88% vs + 6.5% with the 
moderate lipid-lowering strategy, p <0.01). In conclusion, plaque progression in obese 
patients is attenuated using an intensive, but not moderate, lipid-lowering strategy. 
These results highlight the need for aggressive risk factor modification and a decrease in 
vascular inflammation in obese patients. 
These findings provide further evidence in support of the concept that statins possess 
significant nonlipid-lowering properties in vivo (Takemoto & Liao, 2001). It is likely that 
statins inhibit the inflammatory cascade by multiple mechanisms. Statins decrease low-
density lipoprotein (Schectman et al., 2004) and oxidative stress (Stoll et al., 2004), which 
are key promoters of inflammatory events. In addition, it is becoming increasingly 
recognized that statins may exert direct anti-inflammatory effects at the level of the 
arterial wall. Inhibition of isoprenylation by statins results in a decrease in the activation 
and nuclear translocation of the transcription factor, nuclear factor ĸB (Inoue et al., 2002). 
Nuclear factor ĸB plays a central role in directing inflammatory events. Similarly, statins 
inhibit the modification of proteins by myeloperoxidase-catalyzed reactive nitrogen 
species (Shishehbor et al., 2003). These species have been demonstrated to promote 
multiple inflammatory pathways. In support of this observation, atorvastatin therapy has 
been shown to decrease systemic levels of nitrotyrosine, a major product of 
myeloperoxidase-catalyzed pathways (Shishehbor et al., 2003). The ability of statins to 
modulate each of these inflammatory pathways in obese patients in vivo remains to be 
clarified.  
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8. The phosphodiesterase-5 inhibitors 
PDE-5 inhibitors cause an accumulation of NO-driven cGMP and subsequent vasodilatation 
in the corpus cavernosum and in pulmonary vasculature, therefore pharmacological PDE-5 
inhibition has become a widely used treatment for erectile dysfunction (Shabsigh, 2004) and 
pulmonary arterial hypertension (Galiè et al., 2005). Effects of the different PDE-5 inhibitors 
on vasomotor function have also been described (Schäfer et al., 2008; Teixeira et al., 2006). In 
recent years it has been demonstrated, that not only the vascular wall, but also myocardial 
tissue contains PDE-5 (Giordano et al., 2001; Senzaki et al., 2001), 183] and there has been 
considerable interest in the role of the NO–cGMP–protein kinase G (PKG) pathway in 
cardioprotection (Kukreja et al., 2004). Recent studies reported considerable myocardial 
protection (Salloum et al., 2006) and improvement of endothelial dysfunction (Gori et al., 
2005) after ischaemia/reperfusion with pharmacological PDE-5 inhibition, which were 
mediated by cGMP-induced opening of ATP-sensitive K+ channels.  
8.1 Sildenafil citrate 
Sildenafil citrate, a potent PDE-5 inhibitor has been reported to improve the impaired 
endothelial function in smokers (Vlachopoulos et al., 2004), in patients with coronary 
artery disease (Halcox et al., 2002) and most recently in the setting of experimental 
diabetes (Schäfer et al., 2008). In addition, intracellular cGMP accumulation has been 
shown to reduce oxidative tissue injury in conditions associated with increased free 
radical release and oxidative stress (Abdollah et al., 2003) and even in diabetes mellitus 
(Milani et al., 2005). 
Moreover, sildenafil citrate has been shown to display beneficial cardiovascular effects in 
patients with congestive heart failure and pulmonary hypertension, suggesting that it may 
have other systemic benefits involving the endothelium (Galie` et al., 2005). Administration 
of sildenafil citrate in both humans and animals offers protection against ischemic 
phenomena and it reduces the possibility of myocardial infarction after inducing ischemia 
(Bremer et al., 2005). There is little data regarding the long term use of PDE-5 and the effects 
of this on different organs. However, there is evidence that sildenafil citrate may be useful 
as an additional pharmacological strategy to deal with endothelial dysfunction in 
individuals with a high risk of developing CAD, as is the case of diabetic patients. 
We reported recently the results of a double-blind, randomized, controlled trial in 40 male 
patients, age 35–50, with type 2 diabetes. Subjects received sildenafil citrate 50 mg daily (n = 
20) or placebo (n = 20) for 30 days. Levels of hs-CRP, microalbuminuria, homocysteine, A1c 
and erectile function were measured at baseline and to the end of the study. We found that 
men who received sildenafil citrate displayed a significant decrease in the microalbuminuria 
concentrations ( p < 0.01) versus baseline, ( p = 0.02) versus placebo and A1c ( p < 0.01) 
versus baseline, ( p = 0.01) versus placebo (Grover-Páez et al., 2007).  
Vardenafil and Tadalafil have also shown beneficial effects on endothelial function in 
different clinical trials (Schäfer et al., 2008). 
9. Other therapies 
Other therapies such as the use of antioxidants like vitamin E (Economides et al., 2005; 
Paolisso et al., 2003), coenzyme Q (Hamilton et al., 2009), folic acid (Oostrom et al., 2009) and 
allopurinol (Butle et al., 2000, have also demonstrated in several clinical trials some benefits 
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on endothelial function, however more evidence is required to recommend these treatment 
strategies as prevention of endothelial damage in patients with type 2 diabetes mellitus. 
10. Conclusion 
Since endothelial dysfunction is the fundamental substrate for atherosclerosis and 
cardiovascular disease in patients with type 2 diabetes mellitus, it is imperative to study 
integrally to the diabetic patient taking into account both, the clinical manifestations, and 
the inflammation markers like the hsCRP, homocysteine, microalbuminuria, as the most 
important.  
It is therefore of interest to the clinician to know which are the current treatment strategies 
that have demonstrated a real benefit to decrease the endothelial damage or delay it, like the 
use of ACEIs, ARBs, statins, folic acid, 5-PDF inhibitors, antioxidants, among others and 
include them as part of the comprehensive treatment of diabetic patients in addition to 
giving up the harmful habits known such as physical inactivity and smoking.  
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